Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. 2011

Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China.

BACKGROUND Human enterovirus 71 (EV71) has emerged as a significant cause of acute encephalitis and deaths in young children. The clinical manifestations caused by EV71 varied from mild hand, foot and mouth disease to severe neurological complications and deaths, but its pathogenesis remains elusive. Antibody dependent enhancement (ADE) infection has been reported in various viruses and has been shown to contribute to disease severity. RESULTS In this study, the presence of sub-neutralizing antibody was demonstrated to enhance EV71 infection in THP-1 cells and increase the mortality of EV71 infection in a suckling mouse model. Further, a secondary infection model was established to characterize the correlation between ADE and disease severity, and primary asymptomatic EV71 infection was shown to increase the mortality of the secondary EV71 infection in suckling mice. CONCLUSIONS Together, these in vitro and in vivo experiments strongly supported the hypothesis of ADE infection of EV71. The present findings indicate ADE might contribute to the pathogenesis of severe EV71 infection, and raise practical issues of vaccine development and antibody-based therapy.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004769 Enterovirus Infections Diseases caused by ENTEROVIRUS. Infections, Enterovirus,Enterovirus Infection,Infection, Enterovirus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody
D019067 Antibody-Dependent Enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by Fc receptors (RECEPTORS, FC) or by complement receptors (RECEPTORS, COMPLEMENT). Either the virus is complexed with antiviral IMMUNOGLOBULIN G and binds to Fc receptors, or virus is coated with antiviral IMMUNOGLOBULIN M and binds to complement receptors. Antibody Dependent Enhancement,Antibody-Dependent Enhancements,Enhancement, Antibody-Dependent
D029821 Enterovirus A, Human A species of ENTEROVIRUS infecting humans and containing 10 serotypes, mostly coxsackieviruses. EV-A71,Enterovirus 71, Human,Human Enterovirus 71,Human Enterovirus A

Related Publications

Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
October 2010, Clinical and vaccine immunology : CVI,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
August 2013, Medical microbiology and immunology,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
April 2012, Archives of virology,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
January 2017, Clinical and experimental vaccine research,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
June 2012, Uirusu,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
February 2000, The New England journal of medicine,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
December 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
March 2012, Bioorganic & medicinal chemistry letters,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
April 2014, Current opinion in virology,
Jian-Feng Han, and Rui-Yuan Cao, and Yong-Qiang Deng, and Xue Tian, and Tao Jiang, and E-De Qin, and Cheng-Feng Qin
October 2017, Experimental and therapeutic medicine,
Copied contents to your clipboard!